Millions of Americans would be eligible to have popular drugs used for weight loss like Wegovy or Ozempic covered by Medicare ...

About 42% of U.S. adults are obese, the CDC says. GLP-1 medications have changed the picture for people hoping to reduce ...

If the proposal is finalized, it could set the stage for a showdown between the pharmaceutical industry and the Trump ...

Clinical trials show that around one in ten people are ‘non-responders’. Outside of trials, that figure might be much higher.

Most patients still need to be managed by oral medications to treat diabetes and not injections, at least in the early stages ...

The Biden administration wants to expand coverage of anti-obesity medications to millions on Medicare, Medicaid.

The Biden administration is looking to expand access to anti-obesity GLP-1 drugs like Ozempic and Wegovy for people who have ...

More than 200,000 prescriptions for copies of Novo Nordisk's weight-loss drug Wegovy are getting filled by U.S. patients each ...

Millions of Americans with obesity would be eligible to have popular drugs used for weight loss like Wegovy or Ozempic ...

就在 11 月 17 日，这款风靡全球的「减肥神药」正式在中国上市，公立医院首张司美格鲁肽用于减重适应症的处方将于下周在上海开出。 需要注意的是， 司美格鲁肽 是处方药物，针对的是肥胖症患者，这和社交媒体上被大肆宣传的「减肥神药」适用范围或许有所不同 ...

The guidelines are part of a national trend by municipal governments and private firms struggling to manage ballooning costs ...